Imatinib dose escalation versus sunitinib as a second-line treatment against advanced gastrointestinal stromal tumors: A nationwide population-based cohort study

BACKGROUND: Although treatment with imatinib in advanced gastrointestinal stromal tumor (GIST) patients has led to significant clinical benefits, the disease will eventually progress due to imatinib resistance. Treatment options after failure of first-line imatinib include imatinib dose escalation o...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Oncotarget
Hoofdauteurs: Hsu, Jun-Te, Le, Puo-Hsien, Kuo, Chang-Fu, Chiou, Meng-Jiun, Kuo, Chia-Jung, Chen, Tsung-Hsing, Lin, Chun-Jung, Chen, Jen-Shi, Yu, Huang-Pin, Yeh, Chun-Nan, Jan, Yi-Yin, Yeh, Ta-Sen
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Impact Journals LLC 2017
Onderwerpen:
Clinical Research Paper
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5642623/
https://ncbi.nlm.nih.gov/pubmed/29050348
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.16795
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items